Divi's Laboratories Limited Share Price & Analysis
Price Chart
Fundamentals
Strengths
- Strong return on equity (ROE 16.5%)
- Efficient capital deployment (ROCE 22%)
- Virtually debt-free
Concerns
- High premium to book value (P/B 14.4x)
- Trading near 52-week high (₹9,467)
Today's Price Action
The stock is trading at ₹9,100, unchanged from the previous close. Intraday volume matches the 20‑day average at 2,50,084 shares, indicating a neutral participation level without any noticeable surge or drop in buying‑selling activity.
Valuation Snapshot
Divi’s Laboratories Limited carries a trailing P/E of 82.3, considerably higher than the sector median, which is effectively zero due to a mix of non‑profit and loss‑making peers. The company’s return on equity stands at 16.5%, reflecting a solid earnings generation capability relative to its capital base.
Key Levels to Watch
The current price sits near the upper bound of the 52‑week range (₹5,636 – ₹9,270), leaving limited upside room before the historical ceiling is tested. Open‑interest data for the nearest weekly expiry shows a concentration around ₹8,800, which may act as a short‑term pivot point if market participants adjust positions.
Chart Pattern
In the daily chart, a Dragonfly Doji appeared two sessions ago, while a Shooting Star formed nine sessions back. Both patterns emerged on the 1‑day timeframe and signal indecision at the respective price levels where they formed.
Data Summary
Key metrics for the day include a flat price at ₹9,100, a volume equal to the 20‑day average of 2,50,084 shares, and a P/E of 82.3 against a sector P/E of zero. The company’s market capitalization is reported as ₹0 Cr, and it maintains a P/B of 0 with an ROE of 16.5%, while the 52‑week high sits at ₹9,270.
Peer Comparison
| Company | CMP | Mkt Cap | P/E | P/B | ROE % | ROCE % | D/E |
|---|---|---|---|---|---|---|---|
| SUNPHARMA Sun Pharmaceutical Industries Limited | ₹1,899 | ₹4.6L Cr | 36.1 | 5.46 | 16 | 20.5 | 0.07 |
| TORNTPHARM Torrent Pharmaceuticals Limited | ₹4,857 | ₹1.8L Cr | 82.8 | 19.58 | 27.4 | 15.2 | 0.33 |
| APOLLOHOSP Apollo Hospitals Enterprise Limited | ₹8,650 | ₹1.2L Cr | 59.1 | 13.13 | 21.2 | 17.4 | 0.88 |
| CIPLA Cipla Limited | ₹1,385 | ₹1.1L Cr | 31.3 | 3.25 | 11.6 | 15.5 | 0.01 |
| ZYDUSLIFE Zydus Lifesciences Limited | ₹1,120 | ₹1.1L Cr | 23 | 4.16 | 21.2 | 21.1 | 0.38 |
| LAURUSLABS Laurus Labs Limited | ₹1,840 | ₹99K Cr | 90.9 | 18.74 | 18.3 | 17.8 | 0.46 |
| LUPIN Lupin Limited | ₹2,110 | ₹96K Cr | 16.2 | 4.3 | 28.7 | 29.9 | 0.32 |
Showing 7 peers in the same sector · Sorted by market cap
Shareholding Pattern
DIVISLAB · as of Mar 2026
| Category | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Promoters | 51.92% | 51.92% | 51.89% | 51.89% | 51.89% | 51.89% |
| FII | 14.85% | 14.68% | 16.16% | 17.25% | 17.98% | 18.01% |
| DII | 21.78% | 22.10% | 21.66% | 20.98% | 20.44% | 20.63% |
| Public | 11.33% | 11.19% | 10.17% | 9.79% | 9.58% | 9.39% |
| Govt | 0.10% | 0.10% | 0.10% | 0.09% | 0.09% | 0.09% |
Corporate Events
To consider and approve the financial results for the period ended Jun 30, 2026
Dividend - Rs 30 Per Share
To consider and approve the financial results for the period ended March 31, 2026 and dividend
Dividend - Rs 30 Per Share
Dividend - Rs 30 Per Share
Dividend - Rs 30 Per Share
Latest News
All newsDivi's Labs shares update post analyst meet
*Divi's Labs shares update post analyst meet* as the company released transcript from recent investor interaction. No major operational or financial updates were disclosed, keeping sentiment neutral. The event provided clarity on ongoing operations and management outlook. 📊 *STOCKS:* $DIVISLAB | 🏢 *SECTOR:* Pharma | #LOWIMPACT #Pharma
Divi's Labs shares copy of newspaper publication
*Divi's Labs shares copy of newspaper publication.* The company informed the exchange of a newspaper publication, a routine regulatory disclosure. No financial or operational details were provided in the filing. Such notices typically pertain to statutory announcements or investor communications. 📊 *STOCKS:* DIVISLAB | 🏢 *SECTOR:* Pharma | #LOWIMPACT #CorporateFiling
Divi's Labs announces AGM date and dividend record date
*Divi's Labs announces AGM date and dividend record date* — The company has published notice of its 36th Annual General Meeting and set a record date for dividend payout. This is part of routine corporate compliance. No financial surprises or strategic shifts were indicated. 📊 *STOCKS:* DIVISLAB | 🏢 *SECTOR:* Pharma | #LOWIMPACT #Dividend
Divi's Labs announces dividend TDS details for FY26
*Divi's Laboratories announces dividend TDS details for FY26.* The company has informed the exchange about the deduction of income tax at source from dividend payments for FY2025-26. This is a routine compliance disclosure related to dividend disbursement. No financial impact on operations or earnings is expected. 📊 *STOCKS:* DIVISLAB | 🏢 *SECTOR:* Pharma | #LOWIMPACT #Dividend
Financials
Quarterly Results
| Metric | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹2.6K Cr 4.1% | ₹2.7K Cr 12.7% | ₹2.4K Cr 6.8% | ₹2.6K Cr 11.5% | ₹2.3K Cr 0.8% | ₹2.3K Cr 10.4% | ₹2.1K Cr 8.0% | ₹2.3K Cr |
| Op. Profit | ₹890 Cr 0.2% | ₹888 Cr 21.8% | ₹729 Cr 17.7% | ₹886 Cr 19.2% | ₹743 Cr 3.8% | ₹716 Cr 15.1% | ₹622 Cr 14.9% | ₹731 Cr |
| OPM | 34.0% 3.0% | 33.0% 10.0% | 30.0% 11.8% | 34.0% 6.3% | 32.0% 3.2% | 31.0% 6.9% | 29.0% 9.4% | 32.0% |
| Net Profit | ₹583 Cr 15.4% | ₹689 Cr 26.4% | ₹545 Cr 17.7% | ₹662 Cr 12.4% | ₹589 Cr 15.5% | ₹510 Cr 18.6% | ₹430 Cr 20.1% | ₹538 Cr |
| EPS (₹) | 21.96 15.4% | 25.95 26.4% | 20.53 17.7% | 24.94 12.4% | 22.19 15.5% | 19.21 18.6% | 16.2 20.1% | 20.27 |
Values in ₹ Cr · Source: Screener.in
Annual Profit & Loss
| Metric | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ₹10.6K Cr 12.8% | ₹9.4K Cr 19.3% | ₹7.8K Cr 1.0% | ₹7.8K Cr 13.3% | ₹9.0K Cr 28.6% | ₹7.0K Cr 29.2% | ₹5.4K Cr 9.1% | ₹4.9K Cr 27.1% | ₹3.9K Cr 4.3% | ₹4.1K Cr |
| Expenses | ₹7.1K Cr 11.4% | ₹6.4K Cr 13.3% | ₹5.6K Cr 4.4% | ₹5.4K Cr 6.3% | ₹5.1K Cr 23.7% | ₹4.1K Cr 15.0% | ₹3.6K Cr 16.1% | ₹3.1K Cr 17.2% | ₹2.6K Cr 0.3% | ₹2.6K Cr |
| Op. Profit | ₹3.4K Cr 15.8% | ₹3.0K Cr 34.5% | ₹2.2K Cr 6.8% | ₹2.4K Cr 39.0% | ₹3.9K Cr 35.5% | ₹2.9K Cr 57.0% | ₹1.8K Cr 2.6% | ₹1.9K Cr 47.7% | ₹1.3K Cr 12.5% | ₹1.4K Cr |
| OPM | 33.0% 3.1% | 32.0% 14.3% | 28.0% 9.7% | 31.0% 27.9% | 43.0% 4.9% | 41.0% 20.6% | 34.0% 10.5% | 38.0% 15.2% | 33.0% 8.3% | 36.0% |
| Other Income | ₹433 Cr 24.4% | ₹348 Cr 3.9% | ₹335 Cr 2.6% | ₹344 Cr 207.1% | ₹112 Cr 96.5% | ₹57 Cr 69.4% | ₹186 Cr 20.8% | ₹154 Cr 43.9% | ₹107 Cr 48.6% | ₹72 Cr |
| Interest | ₹24 Cr 700.0% | ₹3 Cr 25.0% | ₹4 Cr 100.0% | ₹2 Cr 0.0% | ₹2 Cr 0.0% | ₹2 Cr 71.4% | ₹7 Cr 40.0% | ₹5 Cr 150.0% | ₹2 Cr 33.3% | ₹3 Cr |
| Depreciation | ₹463 Cr 15.2% | ₹402 Cr 6.3% | ₹378 Cr 10.2% | ₹343 Cr 9.9% | ₹312 Cr 21.9% | ₹256 Cr 37.6% | ₹186 Cr 10.1% | ₹169 Cr 19.0% | ₹142 Cr 15.4% | ₹123 Cr |
| PBT | ₹3.4K Cr 16.2% | ₹2.9K Cr 34.8% | ₹2.2K Cr 8.7% | ₹2.4K Cr 35.7% | ₹3.7K Cr 38.2% | ₹2.7K Cr 46.6% | ₹1.8K Cr 1.9% | ₹1.9K Cr 50.7% | ₹1.2K Cr 11.8% | ₹1.4K Cr |
| Tax % | 24.0% 4.0% | 25.0% 3.8% | 26.0% 13.0% | 23.0% 15.0% | 20.0% 23.1% | 26.0% 8.3% | 24.0% 11.1% | 27.0% 6.9% | 29.0% 20.8% | 24.0% |
| Net Profit | ₹2.6K Cr 17.2% | ₹2.2K Cr 36.9% | ₹1.6K Cr 12.2% | ₹1.8K Cr 38.4% | ₹3.0K Cr 49.2% | ₹2.0K Cr 44.1% | ₹1.4K Cr 1.8% | ₹1.4K Cr 54.3% | ₹877 Cr 17.3% | ₹1.1K Cr |
| EPS (₹) | 96.73 17.2% | 82.53 36.9% | 60.27 12.3% | 68.69 38.4% | 111.52 49.2% | 74.75 44.2% | 51.85 1.7% | 50.96 54.2% | 33.04 17.3% | 39.95 |
| Div Payout | 31.0% 13.9% | 36.0% 28.0% | 50.0% 13.6% | 44.0% 63.0% | 27.0% 0.0% | 27.0% 12.9% | 31.0% 0.0% | 31.0% 3.3% | 30.0% 20.0% | 25.0% |
Values in ₹ Cr · Source: Screener.in
Balance Sheet
| Item | Sep 2025 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
Liabilities | ||||||||||
| Equity Capital | ₹53 Cr 0.0% | ₹53 Cr 0.0% | ₹53 Cr 0.0% | ₹53 Cr 0.0% | ₹53 Cr 0.0% | ₹53 Cr 0.0% | ₹53 Cr 0.0% | ₹53 Cr 0.0% | ₹53 Cr 0.0% | ₹53 Cr |
| Reserves | ₹15.4K Cr 3.0% | ₹14.9K Cr 10.3% | ₹13.5K Cr 6.3% | ₹12.7K Cr 8.9% | ₹11.7K Cr 26.3% | ₹9.2K Cr 27.4% | ₹7.3K Cr 5.1% | ₹6.9K Cr 17.6% | ₹5.9K Cr 10.7% | ₹5.3K Cr |
| Borrowings | ₹90 Cr 2150.0% | ₹4 Cr 33.3% | ₹3 Cr 0.0% | ₹3 Cr 25.0% | ₹4 Cr 20.0% | ₹5 Cr 87.2% | ₹39 Cr 63.2% | ₹106 Cr 68.3% | ₹63 Cr 75.0% | ₹36 Cr |
| Other Liabilities | ₹2.6K Cr 35.9% | ₹1.9K Cr 3.3% | ₹1.9K Cr 14.0% | ₹1.7K Cr 1.6% | ₹1.6K Cr 10.7% | ₹1.5K Cr 24.3% | ₹1.2K Cr 21.6% | ₹973 Cr 22.1% | ₹797 Cr 4.6% | ₹762 Cr |
| Total Liabilities | ₹18.2K Cr 7.3% | ₹16.9K Cr 9.5% | ₹15.5K Cr 7.2% | ₹14.4K Cr 8.0% | ₹13.4K Cr 24.0% | ₹10.8K Cr 26.3% | ₹8.5K Cr 6.2% | ₹8.0K Cr 18.4% | ₹6.8K Cr 10.2% | ₹6.2K Cr |
Assets | ||||||||||
| Fixed Assets | ₹5.7K Cr 4.3% | ₹5.4K Cr 14.8% | ₹4.7K Cr 0.3% | ₹4.7K Cr 9.2% | ₹4.3K Cr 16.8% | ₹3.7K Cr 33.1% | ₹2.8K Cr 33.2% | ₹2.1K Cr 4.6% | ₹2.0K Cr 28.0% | ₹1.6K Cr |
| CWIP | ₹2.0K Cr 98.6% | ₹1.0K Cr 31.4% | ₹778 Cr 267.0% | ₹212 Cr 54.9% | ₹470 Cr 33.9% | ₹711 Cr 22.7% | ₹920 Cr 87.0% | ₹492 Cr 310.0% | ₹120 Cr 73.0% | ₹444 Cr |
| Investments | ₹67 Cr 3.1% | ₹65 Cr 20.7% | ₹82 Cr 6.5% | ₹77 Cr 6.9% | ₹72 Cr | ₹0 Cr 100.0% | ₹971 Cr 50.1% | ₹1.9K Cr 3.0% | ₹1.9K Cr 15.8% | ₹1.6K Cr |
| Other Assets | ₹10.4K Cr 0.2% | ₹10.4K Cr 5.4% | ₹9.9K Cr 4.8% | ₹9.4K Cr 10.8% | ₹8.5K Cr 33.6% | ₹6.4K Cr 64.7% | ₹3.9K Cr 9.9% | ₹3.5K Cr 26.3% | ₹2.8K Cr 10.3% | ₹2.5K Cr |
| Total Assets | ₹18.2K Cr 7.3% | ₹16.9K Cr 9.5% | ₹15.5K Cr 7.2% | ₹14.4K Cr 8.0% | ₹13.4K Cr 24.0% | ₹10.8K Cr 26.3% | ₹8.5K Cr 6.2% | ₹8.0K Cr 18.4% | ₹6.8K Cr 10.2% | ₹6.2K Cr |
Values in ₹ Cr · Source: Screener.in
Cash Flow Statement
| Item | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating CF | ₹1.7K Cr 31.1% | ₹1.3K Cr 48.7% | ₹2.5K Cr 28.7% | ₹1.9K Cr 1.8% | ₹1.9K Cr 60.1% | ₹1.2K Cr 27.5% | ₹954 Cr 22.9% | ₹776 Cr 32.5% | ₹1.1K Cr 10.8% | ₹1.0K Cr |
| Investing CF | ₹-804 Cr 198.9% | ₹-269 Cr 90.1% | ₹-2.7K Cr 23.4% | ₹-2.2K Cr 3026.7% | ₹75 Cr 190.4% | ₹-83 Cr 87.9% | ₹-685 Cr 43.3% | ₹-478 Cr 58.1% | ₹-1.1K Cr 180.8% | ₹-406 Cr |
| Financing CF | ₹-799 Cr 0.0% | ₹-799 Cr 0.3% | ₹-797 Cr 49.8% | ₹-532 Cr 1420.0% | ₹-35 Cr 96.8% | ₹-1.1K Cr 343.5% | ₹-246 Cr 21.7% | ₹-314 Cr 15800.0% | ₹2 Cr 100.3% | ₹-631 Cr |
| Net Cash Flow | ₹50 Cr 74.1% | ₹193 Cr 118.5% | ₹-1.0K Cr 28.1% | ₹-816 Cr 141.1% | ₹2.0K Cr 4746.3% | ₹41 Cr 78.3% | ₹23 Cr 235.3% | ₹-17 Cr 230.8% | ₹13 Cr | ₹0 Cr |
| Free Cash Flow | ₹215 Cr 16.7% | ₹258 Cr 87.0% | ₹2.0K Cr 65.7% | ₹1.2K Cr 15.6% | ₹1.0K Cr 3042.4% | ₹33 Cr 85.1% | ₹221 Cr 56.0% | ₹502 Cr 35.1% | ₹774 Cr 20.6% | ₹642 Cr |
Values in ₹ Cr · Source: Screener.in
Key Ratios History
| Metric | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 106d 6.0% | 100d 19.0% | 84d 15.2% | 99d 12.5% | 88d 8.3% | 96d 11.6% | 86d 9.5% | 95d 17.3% | 81d 4.7% | 85d |
| Inventory Days | 311d 14.6% | 364d 3.4% | 352d 3.2% | 341d 3.6% | 329d 4.1% | 316d 8.9% | 347d 10.5% | 314d 2.3% | 307d 4.8% | 293d |
| Days Payable | 88d 6.4% | 94d 5.6% | 89d 7.3% | 96d 17.9% | 117d 17.0% | 100d 4.2% | 96d 0.0% | 96d 7.7% | 104d 85.7% | 56d |
| Cash Conv. Cycle | 330d 10.8% | 370d 6.6% | 347d 0.9% | 344d 14.7% | 300d 3.8% | 312d 7.1% | 336d 7.3% | 313d 10.2% | 284d 11.8% | 322d |
| Working Capital Days | 192d 6.8% | 206d 9.6% | 188d 6.2% | 177d 16.4% | 152d 15.6% | 180d 6.5% | 169d 4.0% | 176d 19.7% | 147d 7.0% | 158d |
| ROCE | 20.0% 25.0% | 16.0% 15.8% | 19.0% 45.7% | 35.0% 9.4% | 32.0% 28.0% | 25.0% 13.8% | 29.0% 31.8% | 22.0% 24.1% | 29.0% 19.4% | 36.0% |
Source: Screener.in · Lower days = better efficiency
Deep Dive Analysis
About Divi's Laboratories Limited
Incorporated in 1990, Divis Laboratories Ltd manufactures and exports API's, Intermediates and Nutraceutical ingredients[1]
HealthcarePharmaceuticals & Biotechnology